Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708056 | 0.93 | HIF1A (0.46) | HIF1AKDM4EALDH1A1GRM5ROCK1 | |
| SCHEMBL6708718 | 0.93 | HIF1A (0.42) | HIF1ANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL6707842 | 0.90 | HIF1A (0.43) | HIF1ANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL6712127 | 0.89 | HIF1A (0.35) | HIF1ARAB9AMEN1KMT2A | |
| SCHEMBL6710375 | 0.87 | HIF1A (0.57) | HIF1AROCK1 | |
| SCHEMBL6711782 | 0.87 | HIF1A (0.41) | HIF1ARAB9AKDM4EALDH1A1GRM5 | |
| SCHEMBL6711807 | 0.86 | HIF1A (0.45) | HIF1ANPC1KDM4EROCK1MEN1 | |
| SCHEMBL6709857 | 0.86 | HIF1A (0.45) | HIF1ANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL6710001 | 0.86 | HIF1A (0.34) | HIF1A | |
| SCHEMBL6710363 | 0.85 | HIF1A (0.39) | HIF1ANPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HIF1A 296/4885NPC1 3891/4885RAB9A 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.